<code id='9A48251887'></code><style id='9A48251887'></style>
    • <acronym id='9A48251887'></acronym>
      <center id='9A48251887'><center id='9A48251887'><tfoot id='9A48251887'></tfoot></center><abbr id='9A48251887'><dir id='9A48251887'><tfoot id='9A48251887'></tfoot><noframes id='9A48251887'>

    • <optgroup id='9A48251887'><strike id='9A48251887'><sup id='9A48251887'></sup></strike><code id='9A48251887'></code></optgroup>
        1. <b id='9A48251887'><label id='9A48251887'><select id='9A48251887'><dt id='9A48251887'><span id='9A48251887'></span></dt></select></label></b><u id='9A48251887'></u>
          <i id='9A48251887'><strike id='9A48251887'><tt id='9A48251887'><pre id='9A48251887'></pre></tt></strike></i>

          
          WSS
          Courtesy Sanofi

          LONDON — In a bid to expand its pipeline of inflammation-targeting drugs, Sanofi said Tuesday it was acquiring California-based Inhibrx in a deal worth up to $2.2 billion.

          The core of the deal is Inhibrx’s experimental therapy for AATD, a disease that progressively damages the lungs and liver. The medicine, INBRX-101, is designed to reduce inflammation and stave off further damage to the tissue. Inhibrx has completed Phase 1 testing of the drug and is enrolling patients in a Phase 2 trial.   

          advertisement

          Inhibrx’s other drug candidates, including its line of cancer-targeting immunotherapies, will be portioned out into a new company that will continue to be called Inhibrx. Mark Lappe, the founder and CEO of Inhibrx, will lead the spun-out company. 

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          Leave your comment

          Please enter your name
          Please enter your comment

          fashion